Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer
Authors
Keywords
-
Journal
ESMO Open
Volume 6, Issue 1, Pages 100044
Publisher
Elsevier BV
Online
2021-01-28
DOI
10.1016/j.esmoop.2020.100044
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The relative risk of second primary cancers in Switzerland: a population-based retrospective cohort study
- (2020) Anita Feller et al. BMC CANCER
- Risks for noncutaneous second primary malignancy in cutaneous malignant melanoma survivors: an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) program
- (2020) Paras P. Vakharia et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Overall survival and second primary malignancies in men with metastatic prostate cancer
- (2020) Juha Mehtälä et al. PLoS One
- Risk of Second Primary Cancers Among Long-Term Survivors of Breast Cancer
- (2020) Dan Li et al. Frontiers in Oncology
- Reduced risk of second primary cancer in patients treated with immune checkpoint inhibitors for a first cancer
- (2020) P. Heudel et al. ANNALS OF ONCOLOGY
- Second primary cancers in non‐Hodgkin lymphoma: Family history and survival
- (2019) Subhayan Chattopadhyay et al. INTERNATIONAL JOURNAL OF CANCER
- Immune evasion before tumour invasion in early lung squamous carcinogenesis
- (2019) Céline Mascaux et al. NATURE
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
- (2019) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non–Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review
- (2019) Qing-Qing Chai et al. Frontiers in Pharmacology
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunological and classical subtypes of oral premalignant lesions
- (2018) Jean-Philippe Foy et al. OncoImmunology
- Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
- (2018) Cheng Xu et al. BMJ-British Medical Journal
- Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials
- (2017) Dennis A. Eichenauer et al. HAEMATOLOGICA
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials
- (2017) Dennis A. Eichenauer et al. HAEMATOLOGICA
- ConSoRe : un outil permettant de rentrer dans le monde du big data en santé
- (2016) Pierre Heudel et al. BULLETIN DU CANCER
- Leveraging premalignant biology for immune-based cancer prevention
- (2016) Avrum Spira et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma
- (2015) Michael Schaapveld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current knowledge and future research directions in treatment-related second primary malignancies
- (2014) Lindsay M. Morton et al. EJC SUPPLEMENTS
- Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors
- (2013) Lois B. Travis et al. Nature Reviews Clinical Oncology
- Risk Factors Associated With Secondary Sarcomas in Childhood Cancer Survivors: A Report From the Childhood Cancer Survivor Study
- (2012) Tara O. Henderson et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer
- (2010) Kerryn W. Reding et al. BREAST CANCER RESEARCH AND TREATMENT
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started